NGEN.V Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: March 30, 2026
Report Source: 2025 3rd Quarter Report
NervGen Pharma Corp. Stock Analysis NGEN.V
Canada Health Care Small Cap Report: NervGen Pharma Corp. operates as a clinical stage biotech company. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2019-03-13. The firm is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.
Read More NervGen Pharma Corp (NGEN.V) Chart
Key Statistics of NervGen Pharma Corp (NGEN.V)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
CAD4.95Volume
66.94KP/E Ratio (TTM)
-52 Week Range
Market Cap
468.81MAvg. Volume
66.94KDividend Yield
-Financial Metrics & Statements of NervGen Pharma Corp (NGEN.V)
FAQ's for NervGen Pharma Corp (NGEN.V)
- According to Musaffa’s Shariah screening methodology, NervGen Pharma Corp (NGEN.V) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.